

### **AMENDMENTS TO THE SPECIFICATION**

Please replace the first full paragraph on page 21 of the specification with the following rewritten paragraph:

RT-PCR was performed essentially as previously described ( Ko, et al., Endocrinology 140:5185-5194. Total RNA (1-2 micro g) was reverse-transcribed at 37 C in a 20 micro L reaction volume using random hexamer (500ng) and MMLV reverse transcriptase (10 units) (New England BioLabs, Boston, MA). Complementary DNA (cDNA) samples (2 micro L) were added to a total 25 micro L reaction mix containing the primers (200 ng each), 0.4 mM dNTP mixture, and Taq DNA polymerase (2.5 U) in 1X PCR buffer (10mM Tris, pH 8.3, 50mM KCl, 1.5mM MgCl<sub>2</sub>, 0.01% gelatin). All PCR amplifications were carried out for 20, 25 or 30 cycles on a MJ Research Minicycler. PCR products were separated by 2% agarose gel electrophoresis, stained with SYBR® Green I (Molecular Probes), and visualized by phosphoimaging technology (FLA-2000; Fuji, Stamford, CT). The following primers were used in the present studies: TM4 (5'-gag aac tcc tga ctg aac tgg acg -3'(SEQ ID NO. 1) and 5'-cca tat tcc ctg ctg agc gta g -3'(SEQ ID NO. 2), 282bp), Khc (5'-aac tga atc gcc tcc aag cag-3' (SEQ ID NO. 3) and 5'-cga act ggc gag aac tgg atg-3' (SEQ ID NO. 4), 195bp),  $\beta$ -tubulin (5'-cct gct cat cag caa gat tcg-3'(SEQ ID NO. 53) and 5'-gtg gtg agc tta agg gta cgg, (SEQ ID NO. 614) 210bp), and inhibin alpha subunit (5'-gct ttc cct ctg ttg acc cac-3' (SEQ ID NO. 75) and 5'-aga tgt tga ggg cag ctc gat-3', (SEQ ID NO. 86) 255bp). L-19 (5'-ctg aag gtc aaa ggg aat gtg-3 (SEQ ID NO. 97) and 5'-gga cag agt ctt gat gat ctc, (SEQ ID NO. 108) 194bp) oligo nucleotide primers were used to amplify ribosomal protein L-19 as an internal control.

Please insert after page 26, but before the claims, the attached paper Sequence Listing in the specification.

Attachments: Sequence Listing (paper copy)

Sequence Listing (computer readable disk copy)